Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) told investors that patient randomization is underway at the Mayo Clinic in Florida, the most recent clinical site to be initiated as part of an ongoing multi-center, randomized two-arm pivotal clinical trial.
The trial is evaluating the investigational Perimeter B-Series OCT medical imaging platform combined with the company’s proprietary ImgAssist AI (artificial intelligence) software.
“Combining high-resolution optical coherence tomography (OCT) with AI algorithms can potentially help surgeons better identify regions of interest during breast-conserving surgeries, with the aim of improving patient outcomes and reducing healthcare costs,” commented Dr Sarah Butler, Perimeter's vice president of Clinical and Medical Affairs
Perimeter CEO Adrian Mendes added: ”We are pleased that we continue to advance our ongoing pivotal clinical trial, supporting our goal to expedite the development of our next-gen AI technology.
“With its potential to become the new standard for specimen imaging technology during breast conservation surgery, our hope is that the data generated from this study will support the commercialization of Perimeter B-Series."
Perimeter Medical Imaging AI (TSX-V:PINK, OTC:PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need.
Contact the author at stephen.gunnion@proactiveinvestors.com